Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Analysts at William Blair raised their Q4 2025 EPS estimates for shares of ARS Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of $0.05 per share for the quarter, up from their prior estimate of $0.02. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.64) per share.

SPRY has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Finally, Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $24.00.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $14.01 on Friday. The company has a market capitalization of $1.36 billion, a P/E ratio of -27.47 and a beta of 0.90. The business has a fifty day simple moving average of $14.63 and a two-hundred day simple moving average of $11.71. ARS Pharmaceuticals has a 1 year low of $4.28 and a 1 year high of $18.51.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 83,695 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $13.00, for a total value of $1,088,035.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Richard E. Lowenthal sold 100,000 shares of ARS Pharmaceuticals stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $12.93, for a total value of $1,293,000.00. Following the sale, the chief executive officer now directly owns 1,398,499 shares of the company’s stock, valued at $18,082,592.07. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,584,351 shares of company stock worth $24,152,378 in the last quarter. 40.10% of the stock is owned by company insiders.

Institutional Trading of ARS Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SPRY. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals in the third quarter worth approximately $30,000. Russell Investments Group Ltd. bought a new position in shares of ARS Pharmaceuticals in the 1st quarter worth $60,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of ARS Pharmaceuticals during the 2nd quarter worth $87,000. Finally, Paloma Partners Management Co purchased a new position in ARS Pharmaceuticals in the first quarter worth $103,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.